Updates are available Correction dated 2024-05-17
Click to view Correction: https://doi.org/10.1186/s41687-024-00728-6
-
Authors
Jain, Rakesh
Ayyagari, Rajeev
Goldschmidt, Debbie
Zhou, Mo
Finkbeiner, Stacy
Leo, Sam
-
Funding
Funding for this research was provided by:
Teva Branded Pharmaceutical Products R&D, Inc.
- License Information
-
More Information
Article History
Received: 10 February 2023
Accepted: 14 November 2023
First Online: 28 November 2023
Change Date: 17 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s41687-024-00728-6
Declarations
:
: The study was approved by Western Institutional Review Board (IRB) and informed consent was obtained from each participant before the interview and before starting the survey.
: Not applicable.
: RJ has received consulting fees and personal fees from and is on the speakers’ bureau and has participated in advisory boards for Adamas, Alkermes, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, and Teva Pharmaceuticals. RA, DG, and MZ are employees of Analysis Group, which has received payments from Teva Branded Pharmaceutical Products R&D, Inc., in relation to this study. SF and SL are employees and/or shareholders of Teva Branded Pharmaceutical Products R&D, Inc.
